Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02581930 · ClinicalTrials.gov registry record · Phase 2

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

A Phase 2 study of Metastatic Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
18
Enrollment target
13
Study locations

NCT02581930 is a Phase 2 study of Metastatic Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (78% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02581930, a Phase 2 study of Metastatic Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
13
Study locations

Study Summary

This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Metastatic Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Recurrent Cutaneous Melanoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Ibrutinib
  • OTHER Pharmacological Study
  • OTHER Pharmacogenomic Study

Study Locations (13)

California

  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • University of California Davis Comprehensive Cancer Center - Sacramento

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill
  • Duke University Medical Center - Durham

Ohio

  • Case Western Reserve University - Cleveland
  • Ohio State University Comprehensive Cancer Center - Columbus

Colorado

  • UCHealth University of Colorado Hospital - Aurora

Florida

  • Moffitt Cancer Center - Tampa

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Missouri

  • Washington University School of Medicine - St Louis

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-08-17
Est. Completion 2026-03-17
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02581930

The ClinicalTrials.gov registry entry for NCT02581930 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (78% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02581930 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT02581930 about?

NCT02581930 is a clinical study titled "Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma". This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

What is the current status of trial NCT02581930?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-08-17. Estimated completion is 2026-03-17.

What conditions does trial NCT02581930 study?

This clinical trial studies the following conditions: Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Recurrent Cutaneous Melanoma.

What interventions are being tested in trial NCT02581930?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ibrutinib (DRUG), Pharmacological Study (OTHER), Pharmacogenomic Study (OTHER).

Who is sponsoring clinical trial NCT02581930?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02581930 being conducted?

This trial has 13 study locations across California, Colorado, Florida, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Melanoma

All registered trials for this condition

Stage IV Cutaneous Melanoma AJCC v6 and v7

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.